title: Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia.
abstract: New studies suggest that polyunsaturated fatty acids, such as omega-3, may reduce the symptoms of schizophrenia. The present study evaluated the preventive effect of omega-3 on interleukines (IL) and neurotrophin brain-derived neurotrophic factor (BDNF) levels in the brains of young rats subjected to a model of schizophrenia. Treatment was performed over 21 days, starting on the 30th day of rat's life. After 14 days of treatment with omega-3 or vehicle, a concomitant treatment with saline or ketamine (25 mg/kg) was started and maintained until the last day of the experiment. BDNF levels in the rat's prefrontal cortex were decreased at 1 h and 24 h after the last administration of ketamine, whereas the group administered with ketamine and omega-3 showed a decrease in BDNF levels only after 24 h. In contrast, both interventions induced similar responses in levels of IL-1β and IL6. These findings suggest that the similarity of IL-1β and IL6 levels in our experimental groups is due to the mechanism of action of ketamine on the immune system. More studies have to be carried out to explain this pathology. In conclusion, according to previous studies and considering the current study, we could suggest a prophylactic role of omega-3 against the outcome of symptoms associated with schizophrenia.
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Alexandra I
authors.initials: AI
authors.lastname: Zugno
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Lara
authors.initials: L
authors.lastname: Canever
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Mastella
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Alexandra S
authors.initials: AS
authors.lastname: Heylmann
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Mariana B
authors.initials: MB
authors.lastname: Oliveira
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Amanda V
authors.initials: AV
authors.lastname: Steckert
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Adalberto A
authors.initials: AA
authors.lastname: Castro
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: Felipe
authors.initials: F
authors.lastname: dal Pizzol
authors.affiliation: Universidade do Extremo Sul Catarinense, Criciúma, SC, BR.
authors.forename: João
authors.initials: J
authors.lastname: Quevedo
authors.affiliation: Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, BR.
authors.forename: Clarissa S
authors.initials: CS
authors.lastname: Gama
mesh_terms: D000818:Animals; D001923:Brain Chemistry; D019208:Brain-Derived Neurotrophic Factor / Q000032:analysis* / Q000187:drug effects; D019587:Dietary Supplements; D004195:Disease Models, Animal; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D007378:Interleukins / Q000032:analysis*; D007649:Ketamine / Q000008:administration & dosage*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012559:Schizophrenia / Q000517:prevention & control*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D015525:Fatty Acids, Omega-3; D007378:Interleukins; D007649:Ketamine